The Life Sciences team advised ElevateBio, LLC on it $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management and joined by a leading group of new and existing investors.

Proceeds from the financing will be used to further advance the company’s technology platforms – Life Edit gene editing, induced pluripotent stem cells, and RNA, cell, protein, vector engineering – and BaseCamp®, its end-to-end genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business, to accelerate the design, manufacturing, and development of cell and gene therapies. The funding will also support ElevateBio’s continued efforts to expand its geographic reach and increase its cGMP manufacturing capacity to provide its academic and industry partners with turnkey and scalable access to technologies and services across the full-product lifecycle.

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come.

The Goodwin team was led by Danielle Lauzon, Gabriela Morales-Rivera, Katie Hand and Jinal Sharma, and included Rich Matheny, Justin Pierce, GG Guckaya and Dan Karelitz.

For more details, read the press release and articles in Fierce Biotech and Reuters.